MPI's new Imaging Center is set to open in Spring 2014 at the company's headquarters in Michigan.

An FDA Committee voted to support approval of GSK and Theravance?s umeclidinium/vilanterol for treatment of chronic pulmonary disease.

FDA specifies the DUNS UFI system for registration of domestic and foreign drug establishments.

The association representing the research-based pharmaceutical industry in Europe is concerned that an EMA policy will put transparency ahead of public-health interests.

The device is an inexpensive, easy-to-use capsule-based DPI with high efficiency powder dispersion and has the versatility to treat a range of pulmonary diseases.

FDA revises boxed warnings for extended-release and long-acting opioid analgesics and postmarket study requirements.

VWR International has signed a global distribution agreement with Thermo Fisher Scientific.

Horizon Pharma reports that FDA has approved the use of Sanofi's manufacturing site in Compiegne, France to manufacture DUEXIS.

Myriad Genetics and AstraZeneca expand their companion diagnostic pact for AztraZeneca?s investigational drug candidate olaparib.

Mylan completes expansion of its transdermal patch facility in Vermont.

Sanofi and POZEN sign a license agreement for the commercialization of omeprazole and aspirin combination product.

FDA inspections reveal possible inaccurate sterility testing.

Following passage in the California Assembly, the California State Senate passes legislation to specify requirements for dispensing biosimilars.

Otsuka's planned acquisition bolsters its pipeline in oncology and adds fragment-based drug-discovery technology.

Rockwell Collins will sell Kaiser Optical Systems to Endress+Hauser.

Meda will acquire Acton Pharmaceuticals.

BioReliance opens Clearance Services Laboratories in Maryland for downstream bioprocessing studies.

Endo will acquire Boca Pharmacal in multimillion dollar deal.

Agilent Technologies opens multimillion dollar Spectroscopy Technology Innovation Center in Australia.

CordenPharma will acquire Peptisyntha SA, based in Belgium.

FDA approves BD Simplist product ondansetron injection, an injectable antiemetic.

Merck & Co gets FDA approval to manufacture bulk varicella at its in Durham, North Carolina for use in chickenpox and shingles vaccines.

Zealand will join efforts with Eli Lilly to design and develop therapeutic peptides for Type 2 diabetes and obesity.

CEO of Waters Corporation will retire within in the next two years.

Capsugel plans to acquire Bend Research to enhance its bioavailability-enhancement capabilities.

Baxter and Coherus Biosciences colaborate to develop and commercialize a biosimilar version of etanercept for Europe, Canada, and, Brazil.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Novartis Ilaris, an interleukin-1 beta inhibitor, treats active system juvenile idiopathic arthritis.